Registry of COPD Patients From Outpatient Polyclinic Healthcare Institutions of the Russian Federation in Moscow

Registry of COPD Patients Who Undergo Outpatient Treatment or Are Under Surveillance at Outpatient Polyclinic Healthcare Institutions of the Russian Federation in Moscow

To describe the clinical profile of COPD patient who is under outpatient surveillance at polyclinic institutions of Moscow (including demographic data (age, gender, ethnicity, occupation), smoking status, disease duration, disease severity grade, distribution by disease phenotype, disease exacerbation rate in the setting of real-life clinical practice).

Study Overview

Status

Unknown

Detailed Description

The registry of COPD patients in fact represents non-interventional multicenter retrospective study including all COPD patients included into the registry retrospectively from patients medical records and newly diagnosed under outpatient surveillance at the selected polyclinic institutions of Moscow.

The registry will include all patients with registered diagnoses J40 - J44 according to ICD-10 with spirometry results confirming COPD diagnosis, who are at the study start under outpatient surveillance, and also newly registered patients diagnosed with COPD (ICD-10 J40 - J44, as confirmed by spirometry results) during the conduction of the registry program at the selected polyclinic institutions of Moscow (according to ICD: J40 - Bronchitis, not specified as acute or chronic, J41 - Simple and mucopurulent chronic bronchitis, J41.0 - Simple chronic bronchitis, J41.8 - Mixed simple and mucopurulent chronic bronchitis, J 42 - Unspecified chronic bronchitis, J 43 - Emphysema, J 44 - Other chronic obstructive pulmonary disease) based on regular (yearly) retrospective analysis of patient records with data entry into a consolidated database.

It is planned to enrol into the study approximately 2000 male and female patients over 40 years of age with diagnosed COPD (as confirmed by spirometry results).

The present observational multicenter descriptive study will be conducted in the setting of routine clinical practice of outpatient polyclinic institutions. There is no hypothesis to be tested in this study.

The study will be conducted in outpatient polyclinic institutions of the primary medical care system of Moscow. Pulmonologists of the primary medical care system will be engaged as investigators. These are the physicians, whom the patients with tentative COPD diagnosis are referred to in the Russian Federation and who within the scope of their responsibilities have access to source medical records and who evaluate the quality of diagnosis and extent of treatment prescribed to COPD patients.

The present study is observational therefore it does not require a treatment regimen or directions for patient management. The patients receive medical care in line with routine practice for treatment of this disease in the Russian Federation. Patient participation in the study should not in any way affect the principles and extent of treatment received by the patient according to routine clinical practice.

Physicians-investigators will enter into the study the information (data) concerning COPD patients, both those already registered at the selected medical treatment and preventive care institution, and newly registered patients as they seek attention at the outpatient polyclinic institutions.

The main purpose of the present study consists in collection of data concerning COPD patients who under surveillance at outpatient polyclinic institutions of Moscow using patient medical records and their medical history. This protocol does not specify any obligatory visits or examinations.

Patient data will be entered into the registry de-identified. The patients will be identified by their screening number and initials. Then the Physician-investigator will evaluate patient compliance with inclusion criteria. The study will enrol patients meeting all the inclusion criteria and not having any of the exclusion criteria.

Only the physician who enters patient data into the regional COPD registry possesses patient contact information, and henceforth only this physician will enter de-identified patient data according to study design. This physician does not influence the choice of examination extent, treatment strategy and medication.

Study Type

Observational

Enrollment (Anticipated)

2000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Moscow, Russian Federation, 105077
        • Recruiting
        • Russian respiratory Society
        • Contact:
          • Olga N Brodskaya, M.D., Ph.D
          • Phone Number: +79166145696
          • Email: rropulmo@mail.ru

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Randomly selected polyclinic institutions of Moscow will take part in the study and enrol into the registry 2000 patients for representativeness of sample for analysis of COPD prevalence in Moscow.

The patient population includes male and female patients over 40 years of age, smokers or ex-smokers, under outpatient surveillance at polyclinic institutions of Moscow with diagnosis codes according to ICD J40 - J44 and diagnosed COPD, as confirmed by spirometry results

Description

Inclusion Criteria:

  • smokers or ex-smokers, with previously diagnosed COPD
  • COPD diagnosis corresponding to ICD codes J40 - J44 (J40 - Bronchitis, not specified as acute or chronic, J41 - Simple and mucopurulent chronic bronchitis, J41.0 - Simple chronic bronchitis, J41.8 - Mixed simple and mucopurulent chronic bronchitis, J 42 - Unspecified chronic bronchitis, J 43 - Emphysema, J 44 - Other chronic obstructive pulmonary disease
  • COPD diagnosis confirmed by spirometry results (spirometry is performed as normal with bronchodilator testing using salbutamol 400 µg, post-BD FEV1\ FVC < 0.7)

Exclusion Criteria:

  • Tuberculosis
  • Sarcoidosis

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
COPD prevalence among patients registered in the healthcare system of Moscow (under outpatient surveillance at polyclinic institutions of Moscow).
Time Frame: 1 day
COPD prevalence among patients registered in the healthcare system of Moscow (under outpatient surveillance at polyclinic institutions of Moscow).
1 day
To describe the clinical profile of COPD patient in Moscow (including demographic data (age, gender, ethnicity, occupation), smoking status, disease duration, disease severity grade
Time Frame: 1 day
To describe the clinical profile of COPD patient who is under outpatient surveillance at polyclinic institutions of Moscow (including demographic data (age, gender, ethnicity, occupation), smoking status, disease duration, disease severity grade, distribution by disease phenotype, disease exacerbation rate in the setting of real-life clinical practice).
1 day

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of patients with different disease phenotypes among outpatients
Time Frame: 1 day
Characterize percentage (%) of COPD patients wth different disease phenotypes among outpatients
1 day
Percentage of prescriptions of medicinal products to COPD patients depending on disease severity grade in the setting of real-life clinical practice
Time Frame: 1 year
Percentage of prescriptions of medicinal products to COPD patients depending on disease severity grade in the setting of real-life clinical practice
1 year
Distribution (%) of COPD patients who seek attention from primary medical care physicians by severity of airway obstruction
Time Frame: 1 year
Distribution (%) of COPD patients who seek attention from primary medical care physicians by severity of airway obstruction
1 year
Mean number of exacerbations requiring medical attention (outpatient prescription of oral corticosteroids and/or antibiotics) in the last year in COPD patients
Time Frame: 1 year
Mean number of exacerbations requiring medical attention (outpatient prescription of oral corticosteroids and/or antibiotics) in the last year in COPD patients
1 year
Mean number of hospitalizations in the last year in COPD patients
Time Frame: 1 year
Mean number of hospitalizations in the last year in COPD patients
1 year
Disease burden based on the collected data concerning the duration of temporary disability
Time Frame: 1 year
Disease burden based on the collected data concerning the duration of temporary disability in days
1 year
Disease burden based on the collected data concerning the outpatient visits due to COPD
Time Frame: 1 year
Disease burden based on the collected data concerning the outpatient visits due to COPD in last year
1 year
To determine the percentage of patients with eosinophilic inflammation according to haematology results
Time Frame: 3 years
To determine the percentage of patients with eosinophilic inflammation according to haematology results
3 years
To describe treatment regimens prescribed to COPD patients depending on disease severity grade in the setting of real-life clinical practice
Time Frame: 3 years
To describe treatment regimens prescribed to COPD patients depending on disease severity grade in the setting of real-life clinical practice
3 years
To establish the percentage of medical prescriptions for treatment of COPD patients which comply with current Federal clinical guidelines for diagnosis and treatment of chronic obstructive pulmonary disease.
Time Frame: 1year
To establish the percentage of medical prescriptions for treatment of COPD patients which comply with current Federal clinical guidelines for diagnosis and treatment of chronic obstructive pulmonary disease.
1year
To evaluate the disease burden based on the collected data concerning the duration of temporary disability of patients under outpatient surveillance
Time Frame: 1 year
To evaluate the disease burden based on the collected data concerning the duration of temporary disability of patients under outpatient surveillance
1 year
To evaluate the disease burden based on the collected data concerning the number of hospitalizations due to COPD exacerbations
Time Frame: 1 year
To evaluate the disease burden based on the collected data concerning the number of hospitalizations due to COPD exacerbations in last year
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Andrey S Belevskiy, M.D., Ph.D., Interregional Public Organization "Russian Respiratory Society'

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2016

Primary Completion (Actual)

January 1, 2019

Study Completion (Anticipated)

February 1, 2019

Study Registration Dates

First Submitted

July 14, 2016

First Submitted That Met QC Criteria

July 28, 2016

First Posted (Estimate)

August 2, 2016

Study Record Updates

Last Update Posted (Actual)

February 4, 2019

Last Update Submitted That Met QC Criteria

February 1, 2019

Last Verified

February 1, 2019

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe